Skip to contentG
GeneDx Holdings Corp.
G
WGSGeneDx Holdings Corp. Q3 2024 · 10-Q
Revenue$76.87M$76.87M+44.2% vs Q3 2023 Net Income-$8.31M-$8.31MN/M vs Q3 2023 EPS Diluted-$0.31-$0.31N/M vs Q3 2023 Gross Profit$47,829,000+89.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GeneDx Holdings Corp. · CIK 1818331 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,395,000N/M Free Cash Flowderived-$5,041,000N/M Margins · derivedGross margin62.2%+14.8 pt vs Q3 2023
Operating margin-10.1%+70.5 pt vs Q3 2023
Net margin-10.8%+68.5 pt vs Q3 2023
ended Sep 30, 2024 · filed Oct 29, 2024 · 29 d after period end